Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06130553 · ClinicalTrials.gov registry record · Phase 1
A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
A Phase 1 study of Advanced Solid Tumors That Are MTAP Deficient, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 234
- Enrollment target
- 20
- Study locations
NCT06130553: Recruiting Phase 1 study of Advanced Solid Tumors That Are MTAP Deficient, sponsored by AstraZeneca.
NCT06130553 is a Phase 1 study of Advanced Solid Tumors That Are MTAP Deficient that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 234 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (290% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06130553, a Phase 1 study of Advanced Solid Tumors That Are MTAP Deficient, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 234 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several study modules, evaluating the safety, tolerability, pharmacokinetic (PK), pharmacodynamics, and preliminary efficacy of AZD3470 as monotherapy or in combination with other anti-cancer agents.
Primary Outcome
Number of participants with AEs and SAEs.
Conditions Studied
Interventions
- DRUG AZD3470
Study Locations (20)
Other
- Research Site - Melbourne
- Research Site - Beijing
- Research Site - Chengdu
- Research Site - Shanghai
- Research Site - Villejuif
- Research Site - Chūōku
- Research Site - Kashiwa
- Research Site - Amsterdam
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Barcelona
- Research Site - Madrid
California
- Research Site - San Francisco
- Research Site - West Hollywood
Connecticut
- Research Site - New Haven
Maryland
- Research Site - Baltimore
Oregon
- Research Site - Portland
Pennsylvania
- Research Site - Pittsburgh
Rhode Island
- Research Site - Providence
Virginia
- Research Site - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2024-01-18 |
| Est. Completion | 2026-02-26 |
| Phase | Phase 1 |
What NCT06130553 shows while recruiting
NCT06130553 is an interventional study that assigns participants to a tested intervention. The registered 234 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (290% higher).
The record links to 1 condition, with Advanced Solid Tumors That Are MTAP Deficient appearing as the primary indexed condition, and to 1 intervention - of which AZD3470 is the first listed.
NCT06130553 names 20 study sites across 8 states, led by Other, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06130553 about?
NCT06130553 is a clinical study titled "A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors". This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several study modules, evaluating the safety, tolerability, pharmacokinetic (PK), pharmacodynamics, and pre...
What is the current status of trial NCT06130553?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 234 participants. The study started on 2024-01-18. Estimated completion is 2026-02-26.
What conditions does trial NCT06130553 study?
This clinical trial studies the following conditions: Advanced Solid Tumors That Are MTAP Deficient.
What interventions are being tested in trial NCT06130553?
The interventions under investigation include: AZD3470 (DRUG).
Who is sponsoring clinical trial NCT06130553?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06130553 being conducted?
This trial has 20 study locations across California, Connecticut, Maryland, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06130553's enrollment target sits among peer trials
234 213th of 2000 higher than 1,787 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
- NCT05444465 · 234 participants · NA
Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
- NCT05720338 · 234 participants · Phase 3
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI